Search results: (10000)
News First Effective Pharmacotherapy Modality for Negative Symptoms in Schizophrenia
Negative symptoms of schizophrenia significantly limit the quality of life and overall functioning of the patient. However, there have been no suitable medications to effectively suppress these symptoms until now. This is expected to change with the introduction of cariprazine into the antipsychotic armamentarium, as suggested by promising results from an analysis published last year in the journal European Psychiatry.
News Genetic Profiling Transforms the Diagnosis and Treatment of Cancer Diseases
Genome sequencing provides doctors with more information about the causes of cancer diseases and changes the ways of treating tumors. Targeted therapy aimed at oncogenic mutations has brought patients longer survival and better clinical outcomes. Let's take a closer look at the advances and challenges of using genomics in oncology.
News Cell-Based Implant as a Stable System for Biological Therapy Delivery
A team of scientists from Washington University in St. Louis focused on the possibility of delivering biological inhibitors for the treatment of rheumatoid arthritis using modified induced pluripotent stem cells. To verify the effectiveness of the therapy, they used a mouse model of rheumatoid arthritis, and their results represent progress in the development of rheumatoid arthritis treatment.
News Increased Sympathetic Activity in Patients with Masked Uncontrolled Hypertension
Not all hypertensive patients who have normal blood pressure readings in the doctor's office actually have controlled hypertension. Recent studies suggest that so-called masked uncontrolled hypertension may be linked to increased sympathetic activity.
News Impact of Body Mass Index on Survival and Treatment Outcomes of Metastatic Colorectal Cancer
A pooled analysis of 25 studies with patients in the first line of treatment for metastatic colorectal cancer (mCRC) evaluated the prognostic and predictive significance of body mass index (BMI). Until its publication in 2015, only the adverse impact of low and high BMI on outcomes in patients with early stages of colorectal cancer was known.
News Position of aPCC in the Treatment of Hemophilia A Complicated by the Development of Inhibitors
Activated prothrombin complex concentrates (aPCC) are essential drugs that not only allow the control of bleeding in patients with congenital hemophilia A and inhibitors but also help to prevent such bleeding. A recent review article by experts from several European institutions provides an up-to-date view of the development, challenges, and future directions in the use of aPCC in the treatment of hemophilia.
News Administration of RAAS Inhibitors in Czech Patients with Heart Failure in Real Practice
A partial analysis of data from the national register of reimbursed health care focused on the epidemiology of heart failure in the Czech Republic showed how inhibitors of the renin-angiotensin-aldosterone system (RAAS), i.e., angiotensin-converting enzyme inhibitors (ACEi), AT1 receptor blockers for angiotensin II (ARBs, sartans), and angiotensin receptor and neprilysin inhibitors (ARNI), were used in real practice in the years 2012–2018 in patients with this disease.
News The Significance of Administering Gliflozins in Real Practice in Diabetics Without CV and Renal Disease
Current care standards recommend the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i, i.e., gliflozins) regardless of glycemic compensation in patients with type 2 diabetes (T2DM) and kidney disease, heart failure, or high cardiovascular (CV) risk. A recent study published in the Clinical Journal of the American Society of Nephrology (CJASN) assessed whether long-term use of SGLT2i brings benefits compared to dipeptidyl peptidase-4 inhibitors (DPP4i, i.e., gliptins) in diabetics without documented CV or renal disease using data from a large Israeli database.
News ESC 2022: What Current Insights Say About the Role of Dabigatran in Stroke Prevention with Atrial Fibrillation and Comorbidities
The risk of atrial fibrillation (AF) increases with age as risk factors accumulate and comorbidities arise. What do current data from randomized clinical trials and registries show about stroke prevention (SP) in the context of concurrent AF and some other chronic diseases? This was the focus of one of the symposia at this year's European Society of Cardiology (ESC) Congress.
News Fatigue in Multiple Sclerosis: What Can Teriflunomide Do?
An article by French authors published in January this year in the journal Multiple Sclerosis and Related Disorders evaluated the effect of teriflunomide on fatigue in patients with multiple sclerosis in real-world practice.
News Combination of Targeted Therapy with Chemo in 1st Line in Patients with Left-Sided wtRAS mCRC
The preferred targeted therapy added to the combination with standard chemotherapy (CHT) for left-sided metastatic colorectal cancer (mCRC) with non-mutated RAS oncogene should be an antibody against the epidermal growth factor receptor (anti-EGFR), not against the vascular endothelial growth factor (anti-VEGF). This is based on a direct comparison of anti-EGFR panitumumab and anti-VEGF bevacizumab in the Japanese phase III PARADIGM study. The results were presented at the ASCO 2022 annual meeting.
News What did the first data from the pilot lung cancer screening show?
Czech pulmonologists have released the first interim results of this year's pilot testing of heavy smokers due to the risk of lung cancer. More than 4,000 patients passed through the hands of general practitioners, and 900 subsequently underwent low-dose CT examination. What other specific findings emerge from the data collection? And what challenges do the experts involved in this program face?
News INFOGRAPHIC: Determining the Target Intraocular Pressure in Glaucoma Therapy
The goal of glaucoma treatment is to preserve the visual field and the quality of life of patients. Currently, the only approach to preserving the visual field of patients is to reduce intraocular pressure (IOP). Its target value should be determined for each patient with consideration of individual risk factors. The following comprehensive infographic shows which factors should be considered according to the current recommendations of the European Glaucoma Society (EGS).
News INFOGRAPHIC: Which treatment to choose in the 1st line for a patient with type 2 diabetes?
Diabetes mellitus is a complex chronic disease that requires continuous treatment and a strategy to reduce associated risks beyond mere glycemic control. Comorbidities and the risk of complications are key elements in deciding the choice of therapy for type 2 diabetics. This fact is also considered by the American Diabetes Association (ADA) in its annually published standards of care for patients with diabetes, which brought several changes in 2022.
News INFOGRAPHIC: Post-Induction Therapy for AML – Current Guidelines
What are the recommended therapeutic modalities for consolidation and maintenance therapy of acute myeloid leukemia (AML) in patients over 60 years of age? We present a clear therapeutic algorithm according to the current recommendations of the American National Comprehensive Cancer Network.
News Over the Last 25 Years, Latanoprost Has Changed the Paradigm of Glaucoma Treatment
An important milestone in the treatment of glaucoma was the introduction of latanoprost with an entirely new mechanism of action compared to previously used antiglaucoma medications. Prostaglandin analogs (PGAs) have become the first-line treatment for primary open-angle glaucoma (POAG) primarily due to their efficacy, once-daily dosing, and minimal systemic side effects. The following recent review briefly summarizes the impact of the introduction of PGAs 25 years ago on current clinical practice in the treatment of glaucoma.
News Efficacy of L. reuteri DSM 17938 in the Treatment of Infantile Colic
Infantile colic represents a syndrome of behavioral disorders in infants characterized by episodes of uncontrollable crying, wailing, and restlessness without an identifiable cause. This is a common health issue affecting an estimated 5–40% of infants. There are no uniform criteria for the treatment of this benign condition yet, but available studies show a beneficial effect from administering probiotics containing Limosilactobacillus reuteri (previously known as Lactobacillus reuteri) compared with placebo and other treatment methods.
News Index of Prostate Health as a Predictive Biomarker of Biopsy Outcome
As demonstrated by Spanish authors in their work published at the beginning of 2018, the Prostate Health Index (PHI) is a biomarker that can refine the prediction of prostate biopsy outcomes in men with elevated prostate-specific antigen (PSA) levels.
News L. reuteri DSM 17938 in Infant Nutrition and Its Impact on the Gut Microbiota of Infants Born by Cesarean Section
The work of the Swiss-Greek team published in the Journal of Pediatric Gastroenterology and Nutrition focused on comparing the effect of infant formula containing Lactobacillus reuteri DSM 17938 on the microbiota of children born by cesarean section or vaginal delivery.
News Pharmacokinetics and Safety of Bilastine 10 mg in Children Aged 6–11 Years
The second-generation antihistamine bilastine is approved in Europe for the treatment of allergic rhinoconjunctivitis and urticaria from the age of 6 years. Recently, results from two post hoc analyses on the pharmacokinetics and safety of bilastine in children aged 6–11 years have been published.
News Impact of the COVID-19 Pandemic on People with Schizophrenia Spectrum Disorders
The COVID-19 pandemic has a far-reaching impact on the physical and mental health of the global population. The current situation poses an undue burden on patients suffering from schizophrenia as well as other psychiatric disorders. According to recent studies, individuals with schizophrenia spectrum disorders have higher mortality rates and worsening disease progression or overall quality of life.
News Regorafenib and Trifluridine/Tipiracil: Hospitalization and Clinical Outcomes in the Treatment of Metastatic Colorectal Cancer
Regorafenib and trifluridine/tipiracil are drugs that prolong overall survival (OS) in pre-treated patients with metastatic colorectal cancer (mCRC). The difference in the toxicity of these agents led to the hypothesis that treatment toxicity of individual drugs might increase the number of hospitalizations, thereby affecting patients' quality of life. The study presented below aimed to analyze the number of hospitalizations during treatment and their possible impact on OS.
News Deficit Alpha-1-Antitrypsin as an Underestimated Problem? What a Survey Among European Experts Revealed
Alpha-1-antitrypsin deficiency (AATD) is a congenital disorder caused by mutations in the SERPINA1 gene. Although it is very well described, it is considered underdiagnosed and undertreated. A recent international survey conducted among specialists on this issue aimed to determine the current situation in Europe.
News From Biomarker Testing to NSCLC Treatment Selection
During a satellite symposium at this year's European Lung Cancer Congress (ELCC 2022), Prof. Martin Reck from the Department of Thoracic Oncology at the hospital in Grosshansdorf, Germany, discussed precision medicine in the treatment of non-small cell lung cancer (NSCLC). We have selected an overview of advancements in next-generation sequencing from his presentation for you.
News Is Six Months of Adjuvant Targeted Therapy Sufficient for Early Breast Cancer?
The inclusion of adjuvant targeted therapy with chemotherapy for early HER2-positive breast cancer significantly improved patient outcomes. Since 2006, based on data from registration studies, the gold standard for adjuvant therapy has been 12 months of trastuzumab administration. However, similar effects were observed in a smaller study with just 9 weeks of treatment. The presented clinical trial therefore investigated the non-inferiority of shorter treatment duration (6 months).